QSS
BCRX icon

Quantitative Systematic Strategies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Quantitative Systematic Strategies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-55,047
Closed -$560K – 479
2021
Q1 		$560K Buy
55,047
+29,849
+118% +$308K 0.09% 352
2020
Q4 		$188K Sell
25,198
-41,502
-62% -$214K 0.03% 565
2020
Q3 		$229K Sell
66,700
-8,551
-11% -$36.6K 0.04% 494
2020
Q2 		$359K Buy
75,251
+30,537
+68% +$122K 0.07% 380
2020
Q1 		$89K Sell
44,714
-56,090
-56% -$154K 0.07% 229
2019
Q4 		$348K Buy
100,804
+57,608
+133% +$145K 0.05% 415
2019
Q3 		$124K Sell
43,196
-394
-0.9% -$1.23K 0.03% 432
2019
Q2 		$165K Buy
43,590
+32,618
+297% +$196K 0.03% 424
2019
Q1 		$89K Sell
10,972
-21,843
-67% -$187K 0.02% 355
2018
Q4 		$265K Buy
32,815
+608
+2% +$4.73K 0.06% 449
2018
Q3 		$246K Buy
+32,207
New +$216K 0.05% 466
2017
Q2 		– Sell
-13,631
Closed -$115K – 441
2017
Q1 		$115K Sell
13,631
-141
-1% -$981 0.03% 343
2016
Q4 		$88K Buy
+13,772
New +$71.7K 0.04% 286
2016
Q3 		– Sell
-63,918
Closed -$186K – 384
2016
Q2 		$186K Buy
+63,918
New +$198K 0.09% 289
2015
Q3 		– Sell
-41,609
Closed -$600K – 371
2015
Q2 		$600K Buy
+41,609
New +$473K 0.13% 267

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Quantitative Systematic Strategies's BCRX Position: Q2 2021 in Review

Quantitative Systematic Strategies sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 55,047 shares — an estimated $560K sold.

Quantitative Systematic Strategies first reported a position in BCRX in Q2 2015 and held it in 15 quarters. The position peaked at $600K in Q2 2015. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

  • Quantitative Systematic Strategies reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 55,047 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $560K.
  • Quantitative Systematic Strategies first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 15 quarters.
  • Quantitative Systematic Strategies's BioCryst Pharmaceuticals position peaked at $600K in Q2 2015.
  • 195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on Quantitative Systematic Strategies's 13F filing for Q2 2021, filed 5 Aug 2021.